This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4 Feb 2011

Merck Ends Drug Discovery Deal with Galapagos

Merck and Galapagos have agreed to end strategic alliances signed in 2008 and 2009, covering metabolic, cardiovascular and inflammatory diseases.

US drug giant Merck and Belgian biotech firm Galapagos NV have agreed to end their drug discovery and development alliances and Galapagos has regained worldwide rights for all assets in the programs.


Merck will make a payment of $16.5 million to Galapagos for work completed in 2010. Galapagos has received a total of $28.7 million in upfront and milestone payments from the alliance and has regained worldwide rights to the targets discovered and assays developed from the collaboration.

“Changes in our early discovery strategy have required us to make some challenging decisions,” said Kathleen Metters, senior vice president, External Discovery and Preclinical Sciences, at Merck. “We look forward to investi

Related News